At the UK Biotech Day 2026, elite life science executives, pioneering R&D scientists, and global health investors gathered to accelerate breakthrough industry partnerships.
Intelligencia AI joined this vibrant ecosystem to demonstrate how purpose-built machine learning removes legacy blind spots from asset evaluation. By equipping cross-functional dealmaking teams with objective, predictive data on a drug’s probability of technical and regulatory success (PTRS), our platform empowers decision-makers to de-risk high-stakes clinical development pipelines and confidently secure market-leading international collaborations.
